目的 探討心舒寶膠囊聯(lián)合纈沙坦膠囊治療高血壓的臨床療效。方法 選取2019年3月-2020年8月在平煤神馬醫(yī)療集團(tuán)總醫(yī)院就診的150例高血壓患者，按照隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各75例。對(duì)照組口服纈沙坦膠囊，80 mg/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服心舒寶膠囊，0.5 g/次，3次/d。兩組患者連續(xù)治療3個(gè)月。觀察兩組的臨床療效，比較兩組的血壓、血清內(nèi)皮素-1（ET-1）、血管緊張素Ⅱ（AngⅡ）、同型半胱氨酸（Hcy）水平。結(jié)果 治療后，治療組的總有效率為94.67%，對(duì)照組的總有效率為84.00%，組間比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的24 h平均收縮壓（24 h SBP）、24 h平均舒張壓（24 h DBP）、收縮壓變異性（SBPV）、舒張壓變異性（DBPV）均明顯降低（P<0.05）；且治療組的24 h SBP、24 h DBP、SBPV、DBPV低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清ET-1、AngⅡ、Hcy水平明顯降低（P<0.05）；且治療后治療組的ET-1、AngⅡ、Hcy水平低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 心舒寶膠囊聯(lián)合纈沙坦膠囊可提高臨床療效，降低血壓，減輕血管內(nèi)皮功能損傷，安全性良好。

Objective To investigate the clinical efficacy of Xinshubao Capsules combined with Valsartan Capsules in treatment of hypertension. Methods Patients (150 cases) with hypertension in Pingmei Shenma Group General Hospital from March 2019 to August 2020 were randomly divided into control and treatment groups, and each group had 75 cases. Patients in the control group were po administered with Valsartan Capsules, 80 mg/time, once daily. Patients in the treatment group were po administered with Xinshubao Capsules on the basis of the control group, 0.5 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the blood pressure, the levels of ET-1, Ang Ⅱ, and Hcy in two groups were compared. Results After treatment, the total effective rates were 94.67% and 84.00% in the treatment group and the control group, and the difference was statistically significant (P<0.05). After treatment, the 24 h SBP, 24 h DBP, SBPV, and DBPV of two groups were significantly decreased (P<0.05). And the 24 h SBP, 24 h DBP, SBPV, and DBPV of the treatment group were lower than those of the control group, and the difference was statistically significant (P<0.05). After treatment, the serum levels of ET-1, Ang Ⅱ, and Hcy in two groups were significantly decreased (P<0.05). After treatment, the levels of ET-1, Ang Ⅱ, and Hcy in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). Conclusion Xinshubao Capsules combined with Valsartan Capsules can improve the curative effect of hypertension, reduce the variability of blood pressure, alleviate the damage of vascular endothelial function, with good safety.

R972

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（LHGJ20191463）